semaglutide news today The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added New project announcement: HHS‑OIG Brand: LifeSeasons Location:UK

semaglutide news today The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed. Added New project announcement: HHS‑OIG Brand: LifeSeasons Location:UK

New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our

If you’re inspired or concerned about recent changes in your hair, our team is here to guide you with personalised solutions tailored to your needs.

Brand: LifeSeasons

Location:UK

GLP-1 agonist semaglutide reduced diabetes risk (HbA1c) and weight (20 lb) in new RCT of people with #schizophrenia, prediabetes, and obesity: Evidence grade: High (10/10) How to use GLP-1’s: #psychiatry #pmhnp There is growing evidence that not only are GLP-1 RAs highly effective in reversing and preventing psychotropic-induced weight gain, but they also might have a direct role in the treatment of several neuropsychiatric disorders, due to a series of properties summarized in this figure (McIntyre RS et al